Clinical Trial
[HuEPO treatment of anemia in preterm infants]
[Article in
Italian]
Affiliations
- PMID: 7870011
Item in Clipboard
Clinical Trial
[HuEPO treatment of anemia in preterm infants]
[Article in
Italian]
Minerva Pediatr.
1994 Nov.
Abstract
The aim of this study is to evaluate how many blood transfusions can be saved by the treatment of anemia in preterm infants (eg < or = 33 weeks) with HUEPO. VLBW infants are at high risk of receiving blood transfusions, following the blood transfusion criteria most applied (45-50% of VLBW infants need blood transfusions). A review of the most recent studies shows that we can save a remarkable number and quantity of blood transfusions in the VLBW infants treated with HUEPO.
Similar articles
-
Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.Pediatrics. 1995 Jan;95(1):1-8. Pediatrics. 1995. PMID: 7770284 Clinical Trial.
-
Optimizing the approach to anemia in the preterm infant: is there a role for erythropoietin therapy?J Perinatol. 1997 Jul-Aug;17(4):276-82. J Perinatol. 1997. PMID: 9280091
-
Recombinant human erythropoietin in anemia of prematurity.Indian Pediatr. 1999 Jan;36(1):17-27. Indian Pediatr. 1999. PMID: 10709119 Clinical Trial.
-
Anemia of prematurity: the prospects for avoiding blood transfusions by treatment with recombinant human erythropoietin.Adv Pediatr. 1993;40:385-403. Adv Pediatr. 1993. PMID: 8249712 Review. No abstract available.
-
Current controversies in the management of the anemia of prematurity.Semin Perinatol. 2009 Feb;33(1):29-34. doi: 10.1053/j.semperi.2008.10.006. Semin Perinatol. 2009. PMID: 19167579 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical